Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211802 · ClinicalTrials.gov registry record · Phase 3
CKM For Safe Use of SGLT2i in Type 1 Diabetes
A Phase 3 study, sponsored by University of California, San Diego.
- Not yet
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT07211802 is a Phase 3 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 52 participants.
The verdict
NCT07211802, a Phase 3 study, has not yet begun recruiting, sponsored by University of California, San Diego.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.
Interventions
- DRUG Sotagliflozin Low Dose
- DRUG Sotagliflozin High Dose
- DEVICE Dual Continuous Glucose and Ketone Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07211802
The ClinicalTrials.gov registry entry for NCT07211802 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sotagliflozin Low Dose is the first listed.
NCT07211802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07211802 about?
NCT07211802 is a clinical study titled "CKM For Safe Use of SGLT2i in Type 1 Diabetes". This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.
What is the current status of trial NCT07211802?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2026-07-01. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT07211802?
The interventions under investigation include: Sotagliflozin Low Dose (DRUG), Sotagliflozin High Dose (DRUG), Dual Continuous Glucose and Ketone Monitor (DEVICE).
Who is sponsoring clinical trial NCT07211802?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.